A plasmid family containing two different expression cassettes suitable for immunomodulation and genetic immunization

Area of Science:

• Molecular Biology
• Immunology
• Biotechnology

Background:

• Eukaryotic expression vectors are crucial for gene expression studies and therapeutic applications.
• Existing vectors may have limitations in driving dual gene expression and optimizing translation.
• Efficient delivery and expression of immunogenic peptides and immunomodulatory cytokines are key for effective genetic immunization.

Purpose of the Study:

• To develop an improved eukaryotic expression vector (pRC110) for enhanced gene expression and genetic vaccination.
• To facilitate the co-expression of an immunogenic peptide and a syngeneic immunomodulating cytokine.
• To optimize translational efficiency for diverse peptide sequences.

Main Methods:

• Construction of the pRC110 vector featuring dual transcription units driven by cytomegalovirus (CMV) and Rous sarcoma virus (RSV) promoters.
• Inclusion of optimal translational start site context for efficient peptide expression.
• In vivo validation through intramuscular gene transfer in a genetic vaccination model.

Main Results:

• Demonstrated successful in vivo expression of encoded peptides and mouse interleukin-2 (IL-2) via intramuscular injection.
• Induction of specific antibodies against the encoded peptide within 3 weeks post-injection.
• Development of a vector family allowing one encoded protein to modulate the other's effects.

Conclusions:

• The pRC110 vector is effective for genetic immunization, enabling simultaneous production of immunogenic peptides and immunomodulatory cytokines.
• The vector's design facilitates efficient expression of various peptides, including partial or synthetic ones.
• pRC110 and its derivatives are valuable tools for immunological studies and developing novel vaccine strategies.